SAGE Therapeutics (SAGE) Reports Q2 Loss of $0.36
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
August 7, 2018 6:30 AM EDTConditional acceptance granted by U.S. Food and Drug Administration (FDA) for the proprietary name ZULRESSO for Sages intravenous formulation of brexanolone
Continuing to execute commercial build and launch readiness for ZULRESSO (brexanolone injection) in postpartum depression ahead of PDUFA target date of December 19, 2018
Accelerating breakthrough pivotal program for SAGE-217 in depression with key trial milestones expected in 4Q 2018
Progressed clinical pipeline with SAGE-718 Phase 1 multiple ascending dose and SAGE-324 Phase 1 single ascending dose trial initiations and planned SAGE-217 Phase 2 trial initiation in bipolar depression
... More